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Significance Statement 
 
Gold(III) complexes are a current focus of research because of their promising anti-cancer properties. Many 
different structural types are being investigated; however, their mode of action remains largely obscure and 
difficult to predict.  
Here we report on the activity of cyclometallated gold(III) dithiocarbamate complexes. We show that the 
antiproliferative properties of these compounds can be correlated with their cellular uptake. Moreover, we 
demonstrate the ability of some of these complexes to selectively stabilize the non-canonical DNA G-quadruplex 
and i-motif structures. We also show that the complexes inhibit the enzyme thioredoxin reductase. On the other 
hand, the involvement of reactive oxygen species (ROS) in the cytotoxicity mechanism could be ruled out. 
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Abstract 
A series of cationic mixed cyclometallated (C^N)Au(III) dithiocarbamate complexes has been 
synthesized in good yields [HC^N = 2-(p-t-butylphenyl)pyridine]. The crystal structure of 
[(C^N)AuS2CNEt2]PF6 (3) has been determined. The cytotoxic properties of the new complexes have 
been evaluated in vitro against a panel of human cancer cell lines and healthy cells and compared with 
a neutral mixed (C^C)Au(III) dithiocarbamate complex (C^C = 4,4′-di-t-butylbiphenyl-2,2′-diyl). The 
complexes appeared to be susceptible to reduction by glutathione but were stable in the presence of N-
acetyl cysteine. The potential mechanism of action of this class of compounds has been investigated 
by measuring the intracellular uptake of some selected complexes, by determining their interactions 
with higher order DNA structures, and by assessing the ability to inhibit thioredoxin reductase. The 
complexes proved unable to induce the formation of reactive oxygen species. The investigations add 
to the picture of the possible mode of action of this class of complexes. 
 
Introduction 
Since the approval in the late 70’s of cis-diamminodichloroplatinum(II) (cisplatin) for the treatment of 
various cancers including testicular, ovarian, prostate or lung cancers,1 the field of metal-based 
anticancer drugs has grown rapidly. However, platinum drugs have several limitations, including 
resistances and heavy side effects affecting fastly growing tissues.2 This has led to a search for the 
possible replacement of platinum by other transition metals, such as iron,3 copper,4 ruthenium5 or 
gold,6 and promising results have been obtained. Organometallic complexes of gold in oxidation states 
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+I and +III have attracted particular attention for anti-cancer purposes due to their high stability in 
physiological media and the ease of their derivatization. The evolution of the field has been regularly 
reviewed.7 Cyclometallated Au(III) with (C^N), (N^N^C) or (C^N^C) ligands have been tested and 
show activities up to low-micromolar range.8,9 Mono-cyclometallated (C^N)Au(III) complexes have 
appeared particularly interesting due to the large palette of (C^N) ligands available, including 
derivatives of N,N-dimethylbenzylamine,10 phenylpyridine,11 benzylpyridine,12 or iminophophorane.13 
A broad range of ancillary ligands is tolerated as well. Some representative examples are collected in 
Figure 1.14 
 
 
Figure 1: Exemples of (C^N) cyclometallated and dithiocarbamate Au(III) complexes investigated for 
anticancer purposes. 
 
Although the mechanism of action of these complexes could not yet be fully elucidated,6a 
investigations have shown that cyclometallated (C^N)Au(III) complexes inhibit several enzymes such 
as cathepsin B and K,12 thioredoxin reductase (TrxR)8c,15 or poly(ADP)-ribose polymerase 1 (PARP-
1).16 Complex B bearing a highly hydrophilic biguanide ligand (Figure 1) has been demonstrated to 
induce reticulum endoplasmic stress and to present anti-angiogenic effects at sub-cytotoxic 
concentrations.17 
Dithiocarbamate (DTC) ligands are also well-known to efficiently stabilize Au(III) cations and 
have been widely used for making anticancer drug candidates (see for example Figure 1 structures C – 
E).7c Complexes based on the scaffold C were highly active in vitro against several human cancer cell 
lines, induced the formation of reactive oxygen species (ROS), and triggered apoptosis via 
mitochondria-related pathways.18,19 Inhibition of proteasomes by Au(DTC) complexes has also been 
demonstrated both in vitro and in vivo.20 
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The association of (C^N) cyclometallated ligands with dithiocarbamates ligands has been 
explored in Au(III)-based drug candidates using either iminophosphorane or phenylpyridine ligands 
(D and E in Figure 1) and gave compounds with in vitro IC50 values in the low to submicromolar 
range against human cancer cells.21,22 From a mechanistic point of view, (C^N)Au(DTC) complexes 
present several features in common with their pure DTC analogues, including cell death through both 
apoptosis and necrosis21 and inhibition of proteasomes.22 Furthermore, complex E has been 
demonstrated to have anti-angiogenic activity, similar to B which bears the same (C^N) ligand, and to 
inhibit deubiquitinases, enzymes regulating the ubiquitination of proteins.22 However, the complete 
mechanism of action of that class of organogold complexes is far from fully elucidated. 
 Here we report the synthesis of a series of gold(III) compounds that combine the stabilisation 
by a cyclometallated (C^N) framework with dithiocarbamate (DTC) ligands, in an effort to probe their 
effect on a panel of human cancer cell lines in vitro, including lung cancer (A549), breast cancer 
(MCF-7 and MDA-MB-231), colon cancer (HCT-116) and leukaemia (HL60) cells and the normal 
human umbilical vein endothelial cells (HUVEC). We also explore their activity against different 
cellular targets associated with each class of compounds, namely the induction of ROS 
(dithiocarbamates), the interaction with non-canonical DNA structures (C^N chelates), and the 
inhibition of TrxR (typical of dithiocarbamates and some cyclometallated compounds). 
 
Results and discussion 
 
Synthesis and characterization 
The (C^N) cyclometalated gold dichloride precursor 1 and the (C^C)Au(DTC) complex 7 were 
synthesized by previously reported methods.22,24 An overnight reaction with sodium dialkyl-
dithiocarbamate hydrate in methanol followed by the addition of aqueous potassium 
hexafluorophosphate or silver hexafluoroantimonate gave the cyclometallated dialkyl-dithiocarbamate 
complexes 2-6 in good yields (71-94 %), as depicted in Scheme 1. 
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Scheme 1: Synthesis of the [(C^N)Au(DTC)]+ complexes 2-6, including the numbering 
scheme used for NMR signal assignments.  
 
 The 1H NMR spectra of complexes 2-6 showed a significant downfield shift in the 
characteristic H2 doublet signal from δ 9.71 to 8.40-8.78 ppm, as well as a downfield shift in the signal 
for H11 from δ 8.03 to 7.03-7.15 ppm, confirming the formation of the different complexes. The 
coordination of the dithiocarbamate ligand was indicated by the observation of two inequivalent alkyl 
groups. The C13{1H} NMR resonance for the NCS2 carbon appeared between δC 190.4 and 198.7 ppm. 
Bands in the IR spectra between 1550 and 1579 cm-1 are attributed to the delocalised dithiocarbamate 
NCS2 system. In the particular case of complex 6 bearing a non-symmetrically substituted DTC ligand 
based on sarcosine ethyl ester, the two possible isomers (Figure 2) were observed in the 1H NMR 
spectrum in a ratio of 1:0.8.  
 
Figure 2: Representation of the two structural isomers of 6. 
 
Slow vapour diffusion of diethyl ether into a concentrated acetonitrile solution of 3 gave crystals 
suitable for X-ray diffraction (Figure 3). There are two independent cations in the unit cell, together 
with two PF6
– anions and a single acetonitrile molecule. The two cations are essentially identical, each 
showing the square planar geometry typical of a gold(III) centre which is slightly distorted due to the 
narrow bite angles of the chelating (C^N) ligands (mean C-Au-N angle 80.75°) and the 
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dithiocarbamates (mean S-Au-S angle 75.61°). Due to the different trans influences of C and N, the 
Au-S bond lengths are significantly different, with mean values 2.3953 and 2.2818 Å in the two 
molecules, similar to those found in related DTC complexes.25 
 
 
Figure 3:  Structure of one of the two cations 3+. Hydrogen atoms, PF6
-anions and the solvent 
molecule are omitted for clarity. Ellipsoids are shown at 50% probability. Selected bond distances [Å] 
and angles [°]: Au1-N1 2.061(3), Au1-C10 2.038(3), Au1-S21 2.3984(8), Au1-S22 2.2821(8), C10-
Au1-N1 80.64(11), C10-Au1-S22 98.36(9), N1-Au1-S21 105.30(7), S22-Au1-S21 75.54(3), N1-Au1-
S22 177.22(7), C10-Au1-S21 173.08(9), S21-C23-S22 111.47(17). 
 
In vitro antiproliferative activity 
Although the dithiocarbamate complexes 2 - 7 were poorly soluble in an aqueous cell culture medium, 
they were soluble enough in DMSO not to precipitate when diluted up to 100 µM in the aqueous 
culture medium with 1% DMSO. IC50 values for the six complexes were then determined on a panel of 
human cancer cell lines. These included solid tumour cell lines; lung adenocarcinoma cells (A549), 
breast adenocarcinoma (MCF-7 and MDA-MB-231) and human colon cancer (HCT-116) and 
suspension cells (promyelocytic leukaemia, HL60), as well as healthy Human Umbilical Vein 
Endothelial Cells (HUVEC) for comparison. Results were determined using a colorimetric MTS assay 
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after 72 h of incubation in comparison to cisplatin (see Experimental part). The results are reported in 
Table 1. 
 
Table 1: IC50 values for complexes 1 - 7 in comparison to cisplatin against different human cancer cell 
lines and healthy HUVEC cells after 72 h of incubation. 
Complex 
IC50 ± SD (µM)
a
 
A549 MCF-7 HL60 HCT-116 
MDA-MB-
231 
HUVEC 
1
b 43.6 ± 4.1 10.8 ± 3.5 6.0 ± 0.5 n. d. n. d. n. d. 
2 4.6 ± 0.7 1.4 ± 0.3 0.2 ± 0.05 2.5 ± 0.3 8.6 ± 1.0 0.8 ± 0.04 
3 2.9 ± 0.6 1.2 ± 0.2 0.2 ± 0.03 2.4 ± 0.4 1.9 ± 0.1 0.7 ± 0.02 
4 10.8 ± 0.3 1.1 ± 0.03 1.4 ± 0.07 6.0 ± 0.4 3.0 ± 0.2 0.7 ± 0.05 
5 5.3 ± 0.3 1.7 ± 0.04 0.8 ± 0.01 3.5 ± 0.3 3.1 ± 0.1 1.2 ± 0.2 
6 >100 >100 17.8 ± 2.1 >100 >100 33.9 ± 5.4 
7 >100 8.8 ± 0.2 1.9 ± 0.3 >100 >100 3.3 ± 0.03 
Cisplatin 33.7 ± 3.7c 21.2 ± 3.9c 3.7 ± 0.3c 5.3 ± 0.2d 28.4 ± 0.1d >100 
aMean ± the standard error of at least three independent experiments. b Values from ref. 26. c Values 
from ref. 27. d Values from ref. 28. 
Complexes 2 - 4 all showed similar cytotoxicity profiles, with high levels of cytotoxicity 
towards all the tested cell lines. The compounds were more active than the dichloro precursor 1 on all 
comparable cell lines. The two complexes presenting the shortest alkyl substituents on the 
dithiocarbamate ligand (2 and 3) showed an activity that was, repectively, 7 and 12 times higher 
thanthat of cisplatin towards A549 lung cancer and more than 15 times more active towards MCF-7 
breast cancer and HL60 leukaemia cells. The complexes also showed more than twice the activity of 
cisplatin towards the colon cancer HCT-116 cells lines, while complex 3 was15 times more active than 
cisplatin against the MDA-MB-231 metastatic breast cancer cells. 
It was thought possible that an increase in lipophilicity of the complex could induce an 
increase in the cellular uptake. However, the more lipophilic pyrrolidine and dibutyl variants 4 and 5 
were slightly less cytotoxic compared to 2 and 3, although they still showed extremely promising 
levels of cytotoxicity in comparison to cisplatin. These results are in line with data reported on similar 
[(C^N)Au(DTC)]+ complexes.22 However, despite their promising anticancer activities all four 
complexes showed poor selectivity towards the Human Umbilical Vein Endothelial Cells (HUVEC), 
with IC50 values in the submicromolar range. Further tests on other healthy cell lines are needed for a 
more accurate conclusion as HUVEC are perhaps not the most reliable comparison,since they typically 
show a reduced sensitivity towards cisplatin.29 
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 The sarcosine ethyl ester dithiocarbamate, complex 6 showed surprisingly low activities across 
the panel of cells, with IC50 values of more than 100 µM for A549, MCF-7, MDA-MB-231 and HCT-
116. This could be due to poor cellular uptake as the complex is highly hydrophilic and therefore 
might struggle to cross the cell membrane. The complex also showed poor activity towards HL60, 
leukaemia cells, with an IC50 of 17.8 µM. In that case, the replacement of the two chlorido ligands by 
the sarcosine ester-based DTC ligand lead to the reduction in the antiproliferative activity of the 
Au(III) complex. However, this complex also showed the best selectivity profile of the new 
dithiocarbamates towards this cell line, (selectivity factor SHL60/HUVEC = 1.9). 
 The neutral (C^C) complex 7 also showed reduced cytotoxicity compared to its cationic (C^N) 
analogue 3, particularly towards the HCT-116, MDA-MB-231 and A549 cells, although it was 
reasonably active towards MCF-7, breast cancer and HL60 leukaemia cells, (IC50 values of 8.8 and 1.9 
µM respectively). Once again, the reduced activity could be due to reduced cellular uptake as the 
(C^C) cyclometalated ligand and the absence of acharge makes this complex very lipophilic. 
 
Reaction with glutathione and N-acetyl cysteine 
Many gold(III) complexes show only weak and reversible binding to DNA, which is the primary target 
of platinum-based drugs.30 However, cytotoxic gold compounds have shown high reactivity towards 
model proteins. Consequently gold-protein interactions are generally thought to be responsible for the 
cytotoxic effects of these complexes and are regarded as their primary targets.6c Metal-protein binding 
sites generally involve the side chain residues of amino acids such as the thioether and thiolate sulphur 
atoms in L-methionine and L-cysteine, respectively.31 Complex 2 as a representative for cationic 
[(C^N)Au(DTC)]+ compounds was reacted with glutathione (GSH) and N-acetyl cysteine (NAC), 
which were selected as reliable models of target biomolecules. Although both GSH and NAC present 
the same thiol group, they have very different redox potentials, with the potential of NAC being 63 
mV more positive than that of GSH. This makes NAC a weaker reductant compared to GSH.32  On 
treating 2 at room temperature with GSH in a 1:1 mixture of DMSO-d6 and D2O, 
1H NMR 
spectroscopy showed the immediate splitting of the signal of the CH2S group (multiplet at 2.75 ppm 
for GSH) into two signals (doublets of doublets at 2.8 and 3.1 ppm) characteristic of the formation of 
oxidized glutathione (GSSG) (Figure 4A).33 Although no signals for the complex could be seen due to 
its poor solubility in these solvents, the formation of a pale-yellow product was observed, which 
suggested reduction to a gold(I) species. This reduction of 2 by GSH could also be followed by 
UV/Vis spectroscopy (Figure 4B). Upon mixing a 1 mM solution of 2 in DMSO with 1 mM of GSH in 
H2O, the characteristic ligand-to-metal charge-transfer (LMCT) band
34 of 2 at 350 nm disappeared, 
confirming that fast reduction occurred, as already observed for gold(III) complexes with bipyridyl 
ligands.35 The appearance of a broad UV/vis band at 400-450 nm could also be tentatively attributed to 
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a gold(I) species.36 The same features could also be seen when other dithiocarbamate derivatives were 
reacted with GSH (Figure S1-5).  
 
Figure 4: a) 1H NMR spectra of a 1:1 mixture of 2 with GSH at room temperature, in comparison with 
the starting materials, GSH and GSSG (DMSO-d6/D2O 1:1).b) UV/Vis spectra of complex 2 (1 mM), 
GSH (1 mM) and a mixture of complex 2 and GSH (1mM), (DMSO-H2O 1:1). 
 
The interaction of 2 and 3 with N-acetyl cysteine (NAC) was also investigated, using NAC as 
a model for thiol containing biomolecules. Boscutti et al. showed that AuIIIBr2(DTC) complexes 
underwent a rapid multi-step reduction in the presence of NAC, during which NAC was oxidized to 
N-acetyl cystine (NACy) and gold(III) was reduced to gold(I), possibly AuBr, with release of 
dithiocarbamate.33a Both 2 and 3 were mixed at room temperature with NAC in CD3CN, and the 
reaction was followed by 1H NMR spectroscopy over a 48 h period (Figure 5 and ESI, Figure S6). No 
reaction was observed for either complexes during this time. It was concluded that the presence of the 
cyclometalated (C^N) ligand rendered the system stable towards reduction by NAC. Indeed, we 
observed neither the disappearance of the SH signal (triplet at 1.8 ppm) nor a shift of the signal due to 
the CH2S group typical of the oxidation of NAC.
33a Thus it appears that Au(III) compounds 
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associating cyclometallated and dithiocarbamate ligands present an intermediate redox stability 
between the pure dithiocarbate and pure cyclometallated complexes. The presence of cyclometallated 
ligand improves the redox stability of the (DTC)Au(III) scaffold (stability in the presence of NAC), 
while on the other hand the DTC ligand decreased the stability of the Au(III) centre against reduction. 
This demonstrate the possibility for fine tuning the redox properties of Au(III) complexes through 
suitable ligand combinations. 
 
Figure 5: 1H NMR spectra of a 1:1 mixture of 2 with NAC at different reaction times at room 
temperature, in comparison with the starting materials 2 and NAC (CD3CN). 
 
Cellular uptake 
Cellular uptake of drugs can have a significant influence on the cytotoxicity of prospective 
chemotherapeutic agents.37 Inductively coupled plasma-mass spectrometry (ICP-MS) was used to 
quantify the amount of intracellular gold and determine whether the uptake of the dithiocarbamate 
complexes correlated with their cytotoxicity. Complexes 2 and 5 (the dimethyl and dibutyl variants) 
were selected as these represented, respectively, the shortest and longest alkyl substituents R in the 
[(C^N)AuIII(S2CNR2)]
+ series. The sarcosine ethyl ester variant 6 was selected because it showed 
extremely poor cytotoxicity towards all tested cell lines, together with 7, the (C^C) diethyl 
dithiocarbamate, as it was charge-neutral and the only complex with a (C^C) ligand. MCF-7 cells were 
incubated for 6 h with 10 µM concentrations of each of the complexes in 1% DMSO. The results of 
three independent experiments are depicted in Figure 6. 
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Figure 6: a) Cellular uptake of complexes 2, 5, 6 and 7 and a DMSO control in MCF-7 cells after 6 h 
of treatment at 10 µM in 1% DMSO. Data represent the average ± standard deviation of three 
experiments. The significance of the results was analysed by t-test. *p value < 0.05. b) Correlation 
between IC50 and cell uptake of complexes 2, 5, 6 and 7 in MCF-7 cells. 
As we previously observed for other organometallic complexes including cyclometallated Au(III) 
complexes,26,27 there was a correlation between the trends in the cellular uptake study (uptake of 2 >> 
5 > 7 > 6) and in the in vitro cytotoxicity study of the complexes (IC50 2 ≈ 5 < 7 << 6) as depicted in 
Figure 6B. The most cytotoxic complexes 2 and 5, which have IC50 values of 1.4 and 1.7 µM 
respectively, both show high levels of uptake, particularly the dimethyl variant, 2 which displays more 
than three times the cellular uptake of complex 5. Complex 7, the neutral (C^C) dithiocarbamate, is 
moderately cytotoxic towards MCF-7 cells with an IC50 of 8.8 µM and also displays quite a low 
cellular uptake. Both 2 and 5 present significantly higher levels of cellular uptake than 7 (28 and 8 
times respectively). Complex 6, the most hydrophilic complex bearing a sarcosine ethyl ester 
substituent, has both very low in vitro cytotoxicity (IC50 value of > 100 µM) and also poor cellular 
uptake. It seems therefore that there is a delicate balance between lipophilicity, charge and solubility 
under physiological conditions which must be met for compounds to be able to cross the phospholipid 
bilayer cell membrane. This behaviour is consistent with our previous observations on the cytotoxicity 
of pincer-stabilised complexes of the type [(C^Npz^C)Au(NHC)]+ (NHC = N-heterocyclic carbene).27 
 
Quantification of reactive oxygen species 
Induction of reactive oxygen species (ROS) is a recognized mechanism of action for metal-based 
drugs, including AuIII(DTC) complexes.18b The cyclometallated dithiocarbamate complexes 
investigated here were therefore tested for the production of ROS. The amount of intracellular ROS 
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was measured after treatment of MCF-7 cells with 100 µM, 50 µM and 10 µM concentrations of each 
complex. The results are summarized in Figure 7. Contrary to what has been observed in the case of 
AuCl2(S2CNMe2),
18b none of the tested complexes appeared to increase the production of ROS and 
therefore this mode of action can be ruled out for these cyclometallated gold dithiocarbamates. 
However, this is in line with reports for other cyclometallated Au(III) complexes,28,38 suggesting that in 
our case of mixed cyclometallated/DTC complexes, the inability to generate ROS is related to the 
cyclometallated ligand structure. 
 
Figure 7:  ROS measurements in MCF-7 cells after 24 h incubation with complexes 2 - 7. 
 
Interactions with non-canonical DNA structures 
Higher-order DNA structures like G-quadruplexes and i-motifs are emerging as promising targets for 
the development of new anticancer agents.39 G-quadruplexes are four-stranded DNA secondary 
structures that form in guanine-rich DNA sequences. They are formed by the stacking of tetrads of 
guanine residues linked via hydrogen-bonding and stabilized by the presence of typically monovalent 
cations in the centre of the tetrad.40 The selective stabilization of G-quadruplex structures has been 
investigated as a method of controlling key cellular events such as telomerase activity or oncogene 
expression making them potentially interestinganticancer targets.39a,b Recently, there have been several 
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examples of potential chemotherapeutic gold(I, III) complexes that target G-quadruplexes.27,41 A 
caffeine-based [Au(NHC)2]
+ cation has been co-crystallized with a G-quadruplex, showing that DNA-
ligand interaction occurred via π-stacking on the accessible tetrads.42 
i-Motifs are higher-order DNA structures that form in cytosine-rich DNA sequences via 
hydrogen bonding between hemiprotonated pairs of cytosines. As i-motifs require cytosine-rich 
sequences, they are likely to form in the complementary strands opposing G-quadruplexes in the 
genome.39c,d Stabilization of i-motif structures has been shown to alter gene expression of the oncogene 
bcl-2 and disrupt telomerase activity, and therefore compounds that stabilize these structures also have 
potential as anticancer drugs.39d 
Cyclometallated Au(III) complexes have been reported to selectively stabilize the non-
canonical DNA G-quadruplex and i-motif structures.27,41b We thus investigated the influence of the 
DTC ligands on the interaction between the cyclometallated Au(III) moiety and G-quadruplexes and i-
motifs. 
 The established Fӧrster resonance energy transfer (FRET) based DNA melting method 
measures the changes in fluorescence as the spatial distance between two fluorophores at the ends of 
DNA is changed as they are brought closer together or moved further apart. Comparison of the 
melting temperature of DNA in the absence and presence of compounds can reveal any compound-
induced DNA stabilization or denaturation.43 Here, FRET results are expressed as the changes in DNA 
melting temperature (∆Tm) when DNA (0.2 µM) is dosed with 50 µM concentrations of each drug. 
Thus the higher ∆Tm is in the presence of a compound, the higher is the DNA stabilization and thus 
the stronger is the compound-DNA interaction. The DNA melting assay was used to give a broad 
indication of the DNA binding capabilities of the dithiocarbamate complexes 2 - 7 towards different 
DNA targets. We used a G-quadruplex forming sequence from the human telomere (hTeloG), the 
human telomeric i-motif sequence (hTeloC), and i-motif forming sequences from the promoter regions 
of HIF-1-α (hif-1-α) and c-Myc (c-MycC), as well as double-stranded DNA.  
The human telomeric i-motif forming sequence, hTeloC is most stable at acidic pH. The 
binding capabilities of the complexes were therefore assessed at a transitional pH of 6.0 (the pH where 
the structure is 50 % folded).44 The c-MYC i-motif, is also more stable at acidic pH, was measured at 
the respective transitional pH of 6.6.39d The remaining sequences were all tested at the transitional pH 
of hif-1-α, pH 7.2.45 Results of the FRET-melting assay with complexes 2 - 7 are depicted in Figure 8. 
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Figure 8: Stabilization of different DNA structures (0.2 µM) in 10 mM sodium cacodylate, 100 mM 
NaCl when dosed with 50 µM concentrations of dithiocarbamate complexes 2 - 7. Data represents the 
average and standard deviations of two experiments. 
 
Complexes 2, 3, 4 and 5 showed high levels of DNA stabilization towards all higher-order 
DNA structures tested. These four complexes showed particularly high levels of stabilization towards 
two of the i-motif forming sequences, the human telomerici-motif sequence, (hTeloC) and the i-motif 
forming sequence from the promoter region of c-Myc (c-MycC). For these two sequences, ∆Tm values 
were between 47-51 °C for complexes 2, 3 and 4 and > 60 °C for complex 5. For the G-quadruplex 
forming sequence, (hTeloG) and the i-motif forming sequence, (hif-1-α), ∆Tm values were somewhat 
lower, between 26-37 °C for all four complexes, indicating lower levels of complex-DNA stabilization 
and thus weaker DNA binding. 
In good agreement with the cytotoxicity data, both 6, the least cytotoxic of the 
[(C^N)Au(DTC)]+ complexes, and 7, the neutral (C^C)Au(DTC), showed only low levels of DNA 
interaction towards all tested structures. For both types of complexes, ∆Tm values were below 10 °C 
for all of the DNA structures tested. These values could be a result of the lack of a cationic charge as 
this is consistent with our previous work, which highlights the importance of a cationic charge on the 
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ability of gold complexes to interact with higher-order nucleic acid structures.27 This suggests that 
mixed cyclometallated/dithiocarbamate Au(III) complexes behave similarly to pure cyclometallated 
Au(III) complexes, with the nature of the DTC ligand acting only to modulate the strength of the gold 
complex/DNA interaction. The results of the FRET-melting assay are generally in good agreement 
with the cytotoxicity data, with the most cytotoxic complexes displaying the highest levels of 
stabilization of the higher-order DNA structures. This suggests that the stabilization of these structures 
could be a possible mechanism of action of these complexes.  
 
Inhibition of thioredoxin reductase 
Thioredoxin reductase (TrxR) is a homodimeric enzyme whose role consists of reducing thioredoxin 
(Trx) in an NADPH-dependent manner. Trx is responsible for the subsequent reduction of different 
proteins including ribonucleotide reductase and peroxiredoxin. Such inhibition of TrxR leads to 
apoptosis through mitochondrial membrane permeabilization and release of cytochrome c.46 Gold 
complexes are well-known to selectively inhibit TrxR over the closely related enzyme glutathion 
reductase via the direct coordination of the gold cation to the selenocysteine residue present in the 
active site of TrxR.47 Considering that dithiocarbamate Au(III) complexes18b and, in some cases 
depending on the ancillary ligand, cyclometallated Au(III) complexes15 have been reported to inhibit 
TrxR, and taking into account the ability of our [(C^N)Au(DTC)]+ complexes to react with the thiol 
containing tripeptide GSH, we tested complex 3, as a representative of that class of compounds, in 
vitro as a potential TrxR inhibitor using mammalian TrxR (see Experimental part for details). The IC50 
of complex 3 was 0.31 ± 0.03 µM, demonstrating TrxR as another potential intracellular target of that 
class of compounds. It is worth noting that this value is intermediate between those of pure 
cyclometallated complexes (tenth to low micromolar range)15 and those of pure dithiocarbamate 
complexes (low nanomolar range).18b This suggests the possibility to modulate the inhibitory activity 
of Au(III) complexes through the association of cyclometallated and dithiocarbamate ligands. 
 
Conclusions 
Cyclometallated gold(III) dithiocarbamate complexes of the type [(C^N)AuIII(S2CNR2)]
+ show 
cytotoxicities that vary with the length and polarity of the N-alkyl substituents R and decrease in the 
order R = Me ≈ Et > pyrrolidine ≈ nBu >> sarcosine ethyl ester, with cationic complexes being much 
more active than neutral (C^C)-chelated analogues. The complexes were tested for their in vitro 
cytotoxicity towards a panel of human cancer cell lines including lung adenocarcinoma cells (A549), 
breast adenocarcinoma (MCF-7 and MDA-MB-231), human colon cancer (HCT-116) and 
promyelocytic leukaemia (HL60), as well as healthy Human Umbilical Vein Endothelial Cells 
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(HUVEC) for comparison. Complexes 2, 3, 4 and 5 showed the highest levels of cytotoxicity with IC50 
values dropping to sub-micromolar levels. The most hydrophilic complex, 6, the sarcosine ethyl ester 
derivative, was non-toxic across all of the cell lines. The most lipophilic complex, the (C^C) derivative 
7, also showed only low cytotoxicity. Cellular uptake studies in MCF-7 breast cancer cells indicated 
that there was a correlation between the in vitro cytotoxicity of the complexes and their ability to enter 
the cell. Complex 2 and 5 both showed high levels of cellular uptake in comparison to 6 and 7. 
However, this correlation is non-linear, and therefore cell uptake is only one of the preconditions for 
cytotoxicity.  
Redox stability and mechanistic studies on targets have been carried out, including ROS 
production for the (DTC)Au(III) complexes and G-quadruplex and i-motif DNA structures for the 
cyclometallated Au(III) compounds, as well as TrxR inhibition studies as a common target to both 
classes of compounds. This has enabled us to investigate the influence of each structural element on 
the pharmacological properties of the other. We observed that cyclometallated gold(III) 
dithiocarbamate complexes presented an intermediate redox stability between the pure cyclometallated 
and pure dithiocarbamate Au(III) complexes. The presence of a cyclometallated ligand completely 
inhibited the ability of the (DTC)Au(III) to generate ROS, while the interaction of the mixed 
complexes with G-quadruplexes and i-motifs followed the same trend as for non-DTC cyclometallated 
Au(III), with only a small influence of the nature of the DTC ligand. Moreover, complex 3 presented 
an intermediate inhibitory activity against TrxR between those of the pure cyclometallated and 
dithiocarbamate Au(III) complexes, suggesting that cyclometallated/dithiocarbamate Au(III) 
complexes should be considered as an independent class of compounds in some cases. Alltogether 
these data highlight the potential of fine tuning the reactivity of this class of organogold complexes.  
For a better understanding of the full mechanism of action, the activity of 
cyclometallated/dithiocarbamate Au(III) complexes against other reported targets of each single 
classes, such as proteasome, PARP-1 or cathepsins, should be investigated. Moreover, beyond those 
reported targets, specific targets of this peculiar class of compound might emerge. 
 
Experimental 
When required, manipulations were performed using standard Schlenk techniques under dry nitrogen 
or in an MBraun glove box. Nitrogen was purified by passing through columns of supported P2O5 with 
moisture indicator, and activated 4 Å molecular sieves. Anhydrous solvents were freshly distilled from 
appropriate drying agents. 1H and 13C{1H} spectra were recorded using a Bruker Avance DPX-300 
spectrometer. 1H NMR spectra (300.13 MHz) were referenced to the residual protons of the deuterated 
solvent used. 13C{1H} NMR spectra (75.47 MHz) were referenced internally to the D-coupled 13C 
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resonances of the NMR solvent. Elemental analyses were carried out at London Metropolitan 
University. (C^N)AuCl2 (1) and compound 7 were synthesized following reported procedures [C^N = 
2-(4′-t-butylphenyl-2′-yl)pyridine].23,24 
Synthesis of complex 2 
A solution of sodium dimethyldithiocarbamate hydrate (0.020 g, 0.140 mmol) in methanol (10 mL) 
was added dropwide to a suspension of (C^N)AuCl2 (0.060 g, 0.125 mmol) in methanol (15mL) and 
stirred at room temperature overnight. A colour change from white to pale yellow was observed during 
the addition. An excess of a saturated aqueous solution of KPF6 was then added, which caused an 
immediate fluffy white precipitation. The solid was filtered off and purified by dissolving in a minimal 
amount of acetonitrile (2 mL) and precipitating with excess diethyl ether (20 mL). The product was 
filtered and dried under vacuum (0.069 g, 0.103 mmol, 82%). Anal.Calcd. for C18H22AuF6N2PS2.5H2O 
(762.51): C, 28.35; H, 4.23; N, 3.67. Found C, 28.15; H, 3.98; N, 3.69.1H NMR ((CD3)2SO, 300 MHz, 
298 K): δ 8.74 (d, 3JH-H = 6.0 Hz, 1H, H
2), 8.43-8.30 (m, 2H, H4+5), 7.99 (d, 3JH-H = 8.2 Hz, 1H, H
8), 
7.60 (t, 3JH-H = 6.0 Hz, 1H, H
3), 7.53 (d, 3JH-H = 8.2 Hz, 1H, H
9), 7.03 (s, 1H, H11), 3.49 (s, 3H, H14/14’), 
3.44 (s, 3H, H14/14’), 1.28 (s, 9H, tBu). 13C{1H} NMR ((CD3)2SO, 75 MHz): δ 193.3 (s, C
13), 163.7 (s, 
C12), 155.8 (s, C6/7), 151.6 (s, C6/7), 150.1 (s, C2), 144.1 (s, C4), 141.8 (s, C10), 127.5 (s, C8), 126.7 (s, 
C
9), 126.2 (s, C3), 124.7 (s, C11), 122.6 (s, C5), 42.5 (s, C14), 41.2 (s, C14’), 35.9 (s, C(CH3)3), 31.2 (s, 
C(CH3)3). IR: νmax (neat)/cm
-1: 1579 (dithiocarbamate). 
Synthesis of complex 3 
Following the procedure described for 2, complex 3 was made from (C^N)AuCl2 (0.060 g, 0.125 
mmol) and NaS2CNEt2·H2O (0.028 g, 0.125 mmol) as a white microcrystalline solid (0.083 g, 0.118 
mmol, 94%). Anal.Calcd. for C20H26AuF6N2PS2·6H2O (808.58): C, 29.71; H, 4.74; N, 3.46. Found C, 
29.46; H, 4.52; N, 3.55.1H NMR ((CD3)2SO, 300 MHz, 298 K): δ 8.78 (d, 
3
JH-H = 5.4 Hz, 1H, H
2), 
8.45-8.31 (m, 2H, H4+5), 8.00 (d, 3JH-H = 8.2 Hz, 1H, H
8), 7.60 (t, 3JH-H = 5.4 Hz, 1H, H
3), 7.54 (dd, 3JH-
H = 8.2 Hz, 
4
JH-H = 1.2 Hz, 1H, H
9), 7.06 (d, 4JH-H = 1.2 Hz, 1H, H
11), 3.87 (m, 4H, H14+14’), 1.35 (m, 
6H, H15+15’), 1.29 (s, 9H, tBu). 13C{1H} NMR ((CD3)2SO, 75 MHz): δ 193.3 (s, C
13), 163.6 (s, C12), 
155.9 (s, C6/7), 151.7 (s, C6/7), 150.1 (s, C2), 144.2 (s, C4), 141.8 (s, C10), 127.5 (s, C8), 126.6 (s, C9), 
126.1 (s, C3), 124.8 (s, C11), 122.6 (s, C5), 48.8 (s, C14), 47.3 (s, C14’), 35.9 (s, C(CH3)3), 31.2 (s, 
C(CH3)3), 13.0 (s, C
15), 12.5 (s, C15’). IR: νmax (neat)/cm
-1: 1559. 
Synthesis of complex 4 
Following the procedure described for 2, complex 4 was made from (C^N)AuCl2 (0.060 g, 0.125 
mmol) and sodium pyrrolidinedithiocarbamate hydrate (0.085 g, 0.502 mmol). A colour change from 
white to pale yellow was observed during the addition. This solid product was filtered and dried under 
vacuum (0.062 g, 0.089 mmol, 71 %). Anal.Calcd. for C20H24AuF6N2PS2.4H2O (770.54): C, 31.18; H, 
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4.19; N, 3.64. Found C, 30.85; H, 3.78; N, 3.25.1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.48 (d, 
3
JH-H 
= 5.6 Hz, 1H, H2), 8.26 (dt, 3JH-H = 8.1 Hz, 
4JH-H = 1.5 Hz, 1H, H
4), 8.07 (d, 3JH-H = 8.1 Hz, 1H, H
5), 
7.72 (d, 3JH-H = 8.3 Hz, 1H, H
8), 7.59-7.50 (m, 2H, H3+9), 7.13 (d, 4JH-H = 1.6 Hz, 1H, H
11), 3.98 (t, 3JH-
H = 6.6 Hz, 4H, H
14+14’), 2.24 (m, 4H, H15+15’), 1.36 (s, 9H, tBu). 13C{1H} NMR (CD2Cl2, 75 MHz): δ 
190.4 (s, C13), 164.4 (s, C12), 157.1 (s, C6/7), 151.8 (s, C6/7), 148.4 (s, C2), 143.6 (s, C4), 140.5 (s, C10), 
126.6 (s, C8), 126.5 (s, C9), 125.3 (s, C3), 125.3 (s, C11), 122.0 (s, C5), 52.0 (s, C14/14’), 35.8 (s, 
C(CH3)3), 30.7 (s, C(CH3)3), 24.6 (s, C
15/15’), 24.2 (s, C15/15’). IR: νmax (neat)/cm
-1: 1556.  
Synthesis of complex 5 
Following the procedure described for 2, complex 5 was made from (C^N)AuCl2 (0.060 g, 0.125 
mmol) and NaS2CN
nBu2 (0.105 g, 0.379 mmol). A colour change from white to pale yellow was 
observed during the addition. The solvent was removed under vacuum and the dark yellow residue 
was dissolved in dichloromethane (15 mL). Excess AgSbF6 in dichloromethane (5mL) was then added 
and the solvent was removed under vacuum. The solid was purified by dissolving in minimal 
acetonitrile (2 mL) and precipitating the product with an excess of diethyl ether (20 mL). This was 
filtered and dried under vacuum (0.073 g, 0.086 mmol, 71 %). Anal.Calcd. for 
C24H34AuF6N2S2Sb·2MeCN (929.49): C, 36.18; H, 4.34; N, 6.03. Found C, 35.70; H, 3.96; N, 6.09.
1H 
NMR (CD3CN, 300 MHz, 298 K): δ 8.40 (d, 
3
JH-H = 5.6 Hz, 1H, H
2), 8.23 (dt, 3JH-H = 8.1 Hz, 
4
JH-H = 
1.4 Hz, 1H, H4), 8.06 (d, 3JH-H = 8.1 Hz, 1H, H
5), 7.71 (d, 3JH-H = 8.1 Hz, 1H, H
8), 7.55-7.44 (m, 2H, 
H3+9), 7.08 (d, 4JH-H = 1.7 Hz, 1H, H
11), 3.77 (m, 4H, H14+14’), 1.78 (m, 4H, H15+15’), 1.42 (m, 4H, 
H16+16’), 1.33 (s, 9H, tBu), 0.98 (m, 6H, H17+17’). 13C{H} NMR (CD3CN, 75 MHz): δ 194.4 (s, C
13), 
163.8 (s, C12), 156.4 (s, C6/7), 151.6 (s, C6/7), 148.9 (s, C2), 143.6 (s, C4), 141.1 (s, C10), 126.7 (s, C8), 
126.5 (s, C9), 125.5 (s, C3), 125.0 (s, C11), 122.1 (s, C5), 53.6 (s, C14/14’), 52.0 (s, C14/14’), 35.5 (s, 
C(CH3)3), 30.2 (s, C(CH3)3), 28.9 (s, C
15/15’), 28.6 (s, C15/15’), 19.6 (s, C16/16’), 12.9 (s, C17/17’). IR: νmax 
(neat)/cm-1: 1550.  
Synthesis of complex 6 
Following the procedure described for 2, complex 6 was made from (C^N)AuCl2 (0.060 g, 0.125 
mmol) and sarcosine ethyl ester dithiocarbamate hydrate (0.100 g, 0517 mmol). The solid was filtered 
and purified by dissolving in minimal acetonitrile (2 mL) and precipitating the product with an excess 
of diethyl ether (20 mL). The product was filtered and dried under vacuum (0.073 g, 0.098 mmol, 78 
%). Anal.Calcd. for C21H26AuF6N2PS2.8H2O (906.64): C, 27.82; H, 4.89; N, 3.09. Found C, 27.34; H, 
4.42; N, 3.29.1H NMR ((CD3)2SO, 300 MHz, 298 K): δ 8.77 (d, 
3JH-H = 5.6 Hz, 0.8H, H
2’), 8.71 (d, 
3
JH-H = 5.6 Hz, 1H, H
2), 8.40-8.27 (m, 3.6H, H4+4’+5+5’), 7.94 (m, 1.8H, H9+9’), 7.63-7.49 (m, 3.6H, 
H3+3’+8+8’), 7.15 (d, 4JH-H = 1.4 Hz, 1H, H
11), 7.01 (d, 4JH-H = 1.4 Hz, 0.8H, H
11’), 4.82 (s, 1.6H, H15’), 
4.78 (s, 2H, H15), 4.21 (m, 3.6H, H17+17’), 3.54 (s, 3H, H14), 3.45 (s, 2.4H, H14’), 1.29 (s, 9H, tBu), 1.27 
(s, 7.2H, tBu’), 1.23 (m, 5.4H, H18+18’). 13C{1H} NMR ((CD3)2SO, 75 MHz): δ 198.7 (s, C
13), 166.3 (s, 
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C
16’), 166.2 (s, C16), 163.5 (s, C12’), 163.3 (s, C12), 156.0 (s, C6’/7’), 156.0 (s, C6/7), 151.5 (s, C6’/7’), 
151.2 (s, C6/7), 150.1 (s, C2’), 150.0 (s, C2), 144.1 (s, C4’), 144.1 (s, C4), 141.6 (s, C10’), 141.4 (s, C10), 
127.4 (s, C8’), 127.4 (s, C8), 126.8 (s, C9’), 126.7 (s, C9), 126.1 (s, C3), 126.0 (s, C3’), 124.7 (s, C11’), 
124.7 (s, C11), 122.5 (s, C5’), 122.5 (s, C5), 62.6 (s, C14’), 62.6 (s, C14), 55.3 (s, C15’), 54.1 (s, C15), 35.9 
(s, C(CH3)3), 31.4 (s, C
17’), 31.1 (s, C(CH3)3), 30.0 (s, C
17), 14.3 (s, C18), 14.3 (s, C18’). IR: νmax 
(neat)/cm-1: 1736 (C=O), 1558 (dithiocarbamate). 
 
X-Ray Diffraction 
Crystal data:  2(C20H26AuN2S2), 2(PF6), MeCN, M = 1442.02; CCDC Code:  1854835. Monoclinic, 
space group P21/c (no. 14), a = 11.9382(2), b = 26.6092(3), c = 16.1416(3) Å, β = 93.060(2) °, V = 
5120.33(14) Å3. Z = 4, Dc = 1.871 g cm
-3, F(000) = 2808, T = 140(1) K, µ(Mo-Kα) = 60.3 cm-1, 
λ(Mo-Kα) = 0.71073 Å. 
Crystals are large, pale yellow-green prisms.  From a sample under oil, one, a block (fragment) ca 0.10 
x 0.21 x 0.33 mm, was mounted on a glass fibre and fixed in acold nitrogen stream on an Oxford 
Diffraction Xcalibur-3/Sapphire3-CCD diffractometer equipped with Mo-Kα radiation and graphite 
monochromator.  Intensity data were measured by thin-slice ω- and φ-scans.  Total no. of reflections 
recorded, to θmax = 27.5°, was 87,240 of which 11,737 were unique (Rint = 0.036); 10,802 were 
'observed' with I> 2σI.  
Data were processed using the CrysAlisPro-CCD and -RED48 programs.  The structure was 
determined by the intrinsic phasing routines in the SHELXT program49 and refined by full-matrix 
least-squares methods, on F2's, in SHELXL.50 The non-hydrogen atoms were refined with anisotropic 
thermal parameters.  Hydrogen atoms were included in idealised positions and their Uiso values were 
set to ride on the Ueq values of the parent carbon atoms.  At the conclusion of the refinement, wR2 = 
0.049 and R1 = 0.029 (47) for all 11,737 reflections weighted w = [σ
2(Fo
2) + (0.0117P)2 + 10.284P]-1 
with P = (Fo
2 + 2Fc
2)/3; for the 'observed' data only, R1 = 0.024. 
In the final difference map, the highest peaks (to ca 1.0 eÅ-3) were close to the gold atoms. 
Scattering factors for neutral atoms were taken from reference 51.  Computer programs used in this 
analysis have been noted above, and were run through WinGX52 on a Dell Precision 370 PC at the 
University of East Anglia. 
 
Antiproliferation assay 
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The human A549 and HL60 cancer cell lines (from ECACC) were cultured in RPMI 1640 medium 
with 10% fetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg mL−1 streptomycin 
(Invitrogen). The cells were maintained under a humidified atmosphere at 37 °C and 5% CO2. The 
human MCF-7, HCT116 and MDA-MB-231 cancer cell lines (from ECACC) were cultured in DMEM 
medium with 10% fetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg mL−1 
streptomycin (Invitrogen). The HUVEC cells were cultured in Endothelial Cell Growth Medium with 
growth and antibiotic supplement. The cells were maintained under a humidified atmosphere at 37 °C 
and 5% CO2. Inhibition of cancer cell proliferation was measured by the 3-(4,5-dimethylthiazol-2-
yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay using the CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (Promega) and following the manufacturer’s 
instructions. Briefly, the cells (3 × 104 per 100 µL for HL60, 8 × 103 per 100 µL for A549, MCF-7, 
HCT116, MDA-MB-231 and HUVEC) were seeded in 96-well plates and left untreated or treated with 
1 µL of DMSO (vehicle control) or 1 µL of complexes diluted in DMSO at different concentrations, in 
triplicate for 72 h at 37 °C with 5% CO2. Following this, MTS assay reagent was added for 4 h and 
absorbance measured at 490 nm using a Polarstar Optima microplate reader (BMG Labtech). IC50 
values were calculated using GraphPad Prism Version 5.0 software. 
Uptake study 
MCF-7 cells were grown in 75 cm2 flasks up to 70% of confluence in 10 mL of culture medium. 
Compounds 2, 5, 6 and 7 were added to the flasks (100 µL of 1 mM solution in DMSO) and incubated 
for 6 h at 37 °C with 5% CO2. Negative controls were used by incubating cells with DMSO alone 
under the same conditions. After removal of the medium and washing of the cells with PBS pH 7.4, 
the cells were detached using a trypsin solution. After quenching of trypsin with fresh medium, 
centrifugation and removal of the supernatant, the cell pellet was resuspended into 1 mL of PBS pH 
7.4 and split into twice 500 µL for metal and protein quantification. The number of cells (expressed 
per million cells) of each sample was determined by measuring the protein content of the treated 
samples using a BCA assay (ThermoFischer Scientific) corrected by the amount of protein/106 cells 
determined for each cell type by measuring the protein content of an untreated sample and dividing by 
the corresponding number of cells measured with a hematocytometer following a reported procedure.53 
Microwave digestion was used to solvate the samples to liquid form. Nitric acid and hydrogen 
peroxide were used in a Milestone Ethos 1 microwave system using SK-10 10 place carousel. The 
digest was ramped to 200°C in 15 min., holding at 200°C for 15 min. The sample was weighed into a 
microwave vessel before digestion, and decanted and rinsed into a pre- weighed PFA bottle after 
digestion. ICP-MS samples were spiked with rhodium internal standard and run on a Thermo X series 
1 ICP-MS. The isotopes selected were 63Cu, 65Cu, 107Ag, 109Ag and 197Au. Certified standards and 
independent reference were used for accuracy. Acid blanks were run through the system and 
subtracted from sample measurements before corrections for dilution. 
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ROS assay 
100 µL of MCF-7 cells were seeded at a density of 1 × 105 cells per mL in a 96-well black plate with a 
transparent bottom. The cells were incubated at 37 °C for 24 h. The medium was removed, and 
replaced with 50 µM H2DCFDA (from Life Technologies) solution in PBS for 40 min. H2DCFDA was 
removed and replaced with fresh medium. The cells were left for recovery for 20 min at 37 °C. Basal 
fluorescence was measured at 485/520 nm on a POLARstar Optima. The cells were incubated with 10 
µM, 50 µM, or 100 µM of compounds, 1% DMSO (negative control) and 100 µM of H2O2 (positive 
control) for 24 h. Fluorescence was read at 485/520 nm. Basal fluorescence was subtracted from the 
fluorescence in the treated cells to calculate the amount of fluorescence caused by the compounds. 
 
FRET melting assay. 
Assessment of compound-induced stabilization of DNA was performed using a fluorescence 
resonance energy transfer (FRET) DNA melting based assay. The sequences used were hTeloCFRET 
(5′-FAM-d[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-TAMRA-3′); hif-1-αFRET (5′-d[CGC-GCT-
CCC-GCC-CCC-TCT-CCC-CTC-CCC-GCG-C]-TAMRA-3′), hTeloGFRET (5′-FAM-d[GGG-TTA-
GGG-TTA-GGG-TTA-GGG]-TAMRA-3′), cMycCFRET (5’-FAM-d[CCC-CAC-CTT-CCC-CAC-
CCT-CCC-CAC-CCT-CCC-C]-TAMRA-3’) and DSFRET FAM-d(TAT-AGC-TAT-A-HEG(18)-TAT-
AGC-TAT-A)-TAMRA-3′). The labelled oligonucleotides (donor fluorophore FAM is 6-
carboxyfluorescein; acceptor fluorophore TAMRA is 6-carboxytetramethyl-rhodamine) were prepared 
as a 220 nM solution in 10 mM sodium cacodylate buffer at the indicated pH with 100 mM sodium 
chloride and then thermally annealed by heating to 95°C in a heat block and cooling overnight. Strip-
tubes (QIAgen) were prepared by aliquoting 20 µL of the annealed DNA, followed by 0.5 µL of the 
compound solutions. Control samples for each run were prepared with the same quantity of DMSO 
with the DNA in buffer. Fluorescence melting curves were determined in a QIAgen Rotor-Gene Q-
series PCR machine, using a total reaction volume of 20 µL. Measurements were made with excitation 
at 470 nm and detection at 510 nm. Final analysis of the data was carried out using QIAgen Rotor-
Gene Q-series software and Origin or Excel. 
 
Inhibition of mammalian TrxR 
To determine the inhibition of mammalian TrxR, an established microplate-reader-based assay was 
performed.54 For this purpose, commercially available rat liver TrxR (Sigma Aldrich) was used and 
diluted with distilled water to achieve a concentration of 3.58 U/mL. The compound was freshly 
dissolved as stock solutions in DMSO. Aliquots (25 mL) of the enzyme solution and either potassium 
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phosphate buffer (25 µL; pH 7.0) containing the compound in graded concentrations or buffer (25 µL) 
without the compound, but DMSO (positive control) were added. A blank solution (DMSO in buffer; 
50µL) was also prepared (final concentrations of DMSO: 0.5% v/v). The resulting solutions were 
incubated with moderate shaking for 75 min at 37°C in a 96-well plate. A portion (225 µL) of the 
reaction mixture (1 mL of reaction mixture consists of: 500 µL potassium phosphate buffer pH 7.0, 80 
µL EDTA solution (100 mM, pH 7.5), 20 µL BSA solution (0.2 %), 100 µL of NADPH solution (20 
mM), and 300 µL distilled water) was added to each well and the reaction was immediately initiated 
by the addition of 20 mM DTNB solution in ethanol (25 µL). After thorough mixing, the formation of 
5-TNB was monitored with a microplate reader at 405 nm ten times in 35 second intervals for about 6 
min. The increase in 5-TNB concentration over time followed a linear trend (r2 = 0.990), and the 
enzymatic activities were calculated as the slopes thereof (increase in absorbance per second). For 
each tested compound, the non-interference with the assay components was confirmed by a negative 
control experiment using an enzyme-free test solution. IC50 values were calculated as the concentration 
of the compounds decreasing the enzymatic activity of the untreated control by 50%, and are given as 
the means and error of three repeated experiments. 
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